Emerging Approaches for Gastric/GEJ Cancers Take the Spotlight at ASCO GI

Emerging treatments, particularly claudin 18.2, a potential new biomarker in the HER2-negative gastric and gastroesophageal junction cancer space, were highlights of the 2023 ASCO Gastrointestinal Cancers Symposium.

Related Keywords

Tennessee ,United States ,New York ,Memorial Sloan Kettering Cancer Center ,Vanderbilt University ,American ,Kohei Shitara ,Cathy Eng ,Steve Maron ,Davidh Johnson ,American Society Of Clinical Oncology ,European Society Of Medical Oncology ,Tn Vanderbilt Ingram Cancer Center Codirector ,Oncology At Vanderbilt University Medical Center ,Vanderbilt Ingram Cancer Center ,Clinical Oncology ,Gastrointestinal Cancers Symposium ,Targeted Therapies ,Assistant Attending Physician ,Steven Maron ,Medical Oncology ,Vanderbilt University Medical Center ,European Society ,News ,Articles ,Publications ,Gi Cancers ,Pagej ,Gastroesophageal ,Oesophageal ,Potlight Phase 3 Trial ,Nct03504397 ,